MDT

85.26

-0.95%↓

A

120.85

-0.66%↓

VEEV

168.97

+0.64%↑

HQY

86.11

+0.21%↑

NEOG

9.63

+1.37%↑

MDT

85.26

-0.95%↓

A

120.85

-0.66%↓

VEEV

168.97

+0.64%↑

HQY

86.11

+0.21%↑

NEOG

9.63

+1.37%↑

MDT

85.26

-0.95%↓

A

120.85

-0.66%↓

VEEV

168.97

+0.64%↑

HQY

86.11

+0.21%↑

NEOG

9.63

+1.37%↑

MDT

85.26

-0.95%↓

A

120.85

-0.66%↓

VEEV

168.97

+0.64%↑

HQY

86.11

+0.21%↑

NEOG

9.63

+1.37%↑

MDT

85.26

-0.95%↓

A

120.85

-0.66%↓

VEEV

168.97

+0.64%↑

HQY

86.11

+0.21%↑

NEOG

9.63

+1.37%↑

Search

Charles River Laboratories International Inc

Chiusa

SettoreSettore sanitario

185.91 0.92

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

179.82

Massimo

186.69

Metriche Chiave

By Trading Economics

Entrata

-332M

-277M

Vendite

-11M

994M

Margine di Profitto

-27.816

Dipendenti

18,300

EBITDA

730K

198M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+7.3% upside

Dividendi

By Dow Jones

Utili prossimi

6 mag 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

859M

8.8B

Apertura precedente

184.99

Chiusura precedente

185.91

Notizie sul Sentiment di mercato

By Acuity

7%

93%

11 / 348 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bullish Evidence

Charles River Laboratories International Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

20 apr 2026, 23:49 UTC

Principali Notizie su Eventi

New Zealand 1Q Inflation Higher Than Expected

20 apr 2026, 23:10 UTC

Azioni calde

Stocks to Watch: Amazon, Alaska Air Group, BridgeBio Oncology, AXT

20 apr 2026, 22:53 UTC

I principali Market Mover

BridgeBio Oncology Shares Rise After FDA Fast-Tracks Pancreatic Cancer Treatment

20 apr 2026, 23:45 UTC

Discorsi di Mercato

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

20 apr 2026, 23:44 UTC

Discorsi di Mercato

Gold Consolidates as End of Cease-Fire Looms -- Market Talk

20 apr 2026, 23:39 UTC

Discorsi di Mercato

Rio Tinto Posts Strong Start to Year -- Market Talk

20 apr 2026, 23:30 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

20 apr 2026, 23:30 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

20 apr 2026, 23:30 UTC

Discorsi di Mercato

Super Retail's Earnings Outlook Less Rosy -- Market Talk

20 apr 2026, 23:09 UTC

Discorsi di Mercato

Viva Energy's Refinery Fire More Benign Than Jefferies Thought -- Market Talk

20 apr 2026, 22:31 UTC

Acquisizioni, Fusioni, Takeovers

Anthropic, Amazon Tighten Bond in $5 Billion Investment and Computing Deal -- WSJ

20 apr 2026, 22:26 UTC

Acquisizioni, Fusioni, Takeovers

West African Resources Says Sanbrado, Toega Operations Not Subject to Govt Request for Additional Participation

20 apr 2026, 22:25 UTC

Acquisizioni, Fusioni, Takeovers

West African Resources Plans to Distribute Cash Proceeds to Shareholders Via Special Dividend

20 apr 2026, 22:25 UTC

Acquisizioni, Fusioni, Takeovers

West African Resources Aims for Acquisition to Be Completed by End-2026

20 apr 2026, 22:25 UTC

Acquisizioni, Fusioni, Takeovers

West African Resources Says to Work Cooperatively With Govt to Finalize Deal Terms

20 apr 2026, 22:25 UTC

Acquisizioni, Fusioni, Takeovers

West African Resources Says Acquisition Would Be for A$175 Million

20 apr 2026, 22:24 UTC

Acquisizioni, Fusioni, Takeovers

West African Resources Says Burkina Faso Govt Issues Decree to Acquire 25% of Kiaka

20 apr 2026, 22:15 UTC

Acquisizioni, Fusioni, Takeovers

Anthropic, Amazon Tighten Bond in $5 Billion Investment and Computing Deal -- WSJ

20 apr 2026, 22:01 UTC

Acquisizioni, Fusioni, Takeovers

Amazon Invests $5B in Anthropic Amid Expanded Collaboration

20 apr 2026, 21:38 UTC

Discorsi di Mercato

Apple's New CEO Will Face Immediate Pressure on AI Strategy -- Market Talk

20 apr 2026, 21:33 UTC

Acquisizioni, Fusioni, Takeovers

Uber Expands Stake In Lucid for Robo-Taxis. This Is How Tesla's Stock Is Responding. -- Barrons.com

20 apr 2026, 21:24 UTC

Discorsi di Mercato

Apple's CEO Change Timing Will Garner Mixed Reaction, Analyst Says -- Market Talk

20 apr 2026, 21:24 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

20 apr 2026, 21:13 UTC

Utili

Alaska Air: Expansion of Card Portfolio Expected to Accelerate Loyalty Platform Beyond Incremental $150M Profit Outlined in Alaska Accelerate Strategy

20 apr 2026, 21:10 UTC

Utili

Alaska Air to Move Toward a Single Issuer for Atmos Rewards Credit Cards

20 apr 2026, 21:09 UTC

Utili

Alaska Air Sees 2Q Capacity Up About 1% Year-Over-Year, Down Nearly a Point From Original Views, on 'Proactive Trimming' of May and June Capacity

20 apr 2026, 21:08 UTC

Utili

Alaska Air 'Continues to Operate From a Position of Strength,' With Healthy Balance Sheet, Strong Liquidity, About $20B in Unencumbered Assets

20 apr 2026, 21:07 UTC

Utili

Alaska Air: Taken Together, Rev, Cost and Fuel Assumptions Result in 2Q Adjusted Loss Per Share Estimate of About $1

20 apr 2026, 21:05 UTC

Utili

Alaska Air: This Assumption Adds About $600M of Expense to 2Q, Equivalent to EPS Headwind of $3.60

20 apr 2026, 21:05 UTC

Utili

Alaska Air Expects 2Q Fuel Cost to Average About $4.50 Based on Forward Curve Today

Confronto tra pari

Modifica del prezzo

Charles River Laboratories International Inc Previsione

Obiettivo di Prezzo

By TipRanks

7.3% in crescita

Previsioni per 12 mesi

Media 197.3 USD  7.3%

Alto 235 USD

Basso 160 USD

Basato su 11 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Charles River Laboratories International Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

11 ratings

7

Acquista

4

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

117.16 / 144.77Supporto e resistenza

A breve termine

Strong Bullish Evidence

A termine intermedio

Weak Bullish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

11 / 348 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste molto forti

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat